Treatment, Medication & Supplement Directory
A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.
Named profile Palladia (Toceranib): Approved Canine Mast Cell Tumor Targeted TherapyRepresentative category illustration – no product packaging is shown.Palladia (Toceranib): Approved Canine Mast Cell Tumor Targeted Therapy
Palladia is an FDA-approved prescription veterinary tyrosine kinase inhibitor for treatment of Patnaik grade II or III recurrent canine cutaneous mast cell tumors, with or without regional lymph-node…
Read moreNamed profile Laverdia (Verdinexor): FDA-Approved Oral Therapy for Canine LymphomaRepresentative category illustration – no product packaging is shown.Laverdia (Verdinexor): FDA-Approved Oral Therapy for Canine Lymphoma
Verdinexor is an oral prescription antineoplastic for certain dogs with lymphoma. FDA announced full approval in January 2026 after the product's earlier conditional-approval pathway; publication should use the…
Read more
Radiation Therapy: Local Control and Symptom Relief
Radiation therapy uses planned ionizing radiation to damage tumor cells while limiting exposure to surrounding normal tissue. The number of visits, dose per visit, imaging, anesthesia, expected control,…
Read moreStereotactic Radiation Therapy: Precision and Evidence Questions
Stereotactic radiation delivers a highly conformal plan in relatively few treatment sessions for selected targets, with strict imaging, immobilization, and specialist quality assurance.
Read morePalliative-Intent Radiation: Symptom Goal and Tradeoffs
Palliative radiation uses a comfort-focused treatment plan for selected painful or obstructive tumors and must be evaluated by symptom goal, burden, and field-specific risk.
Read moreTyrosine Kinase Inhibitors: A Class-Level Monitoring Framework
Tyrosine kinase inhibitors are not one interchangeable drug class; target profile, label, evidence, dosing, monitoring, and adverse effects differ by product and patient.
Read moreImatinib in Canine Mast Cell Tumor Care: Extra-Label Evidence Review
Imatinib has published canine mast cell tumor experience but is not interchangeable with veterinary-labeled TKIs and requires specialist, legal, formulation, and evidence review.
Read moreNamed profile Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell TumorsRepresentative category illustration – no product packaging is shown.Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell Tumors
Masitinib is an oral canine TKI with an EMA veterinary authorization for a defined mast cell tumor setting; the current regional label governs eligibility and monitoring.
Read more
Named profile Oncept Canine Melanoma Vaccine, DNA: USDA-Licensed Therapeutic BiologicRepresentative category illustration – no product packaging is shown.Oncept Canine Melanoma Vaccine, DNA: USDA-Licensed Therapeutic Biologic
Oncept is a USDA-listed canine melanoma DNA biologic; license status, specialist access, intended setting, evidence limitations, and cost require current review.
Read more
Named profile Stelfonta (Tigilanol Tiglate): Intratumoral Canine Mast Cell Tumor TherapyRepresentative category illustration – no product packaging is shown.Stelfonta (Tigilanol Tiglate): Intratumoral Canine Mast Cell Tumor Therapy
Stelfonta is an FDA-approved intratumoral treatment for narrowly defined canine mast cell tumors, with important current warnings about degranulation, wounds, pain, tissue loss, amputation, and death.
Read more